Catestatin, an endogenous Chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum

Cellular and Molecular Life Sciences

Volumn 67, Issue 6, 2010, Pages 1005-1015

  Akaddar, Aziza ^a   Doderer Lang, Cécile ^a   Marzahn, Melissa R ^b   Delalande, François ^a   Mousli, Marc ^a   Helle, Karen ^c   Van Dorsselaer, Alain ^d   Aunis, Dominique ^a   Dunn, Ben M ^b   Metz Boutigue, Marie Hélène ^a   Candolfi, Ermanno ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BERGEN   (Norway)

^d CNRS   (France)

Author keywords

Antimicrobial peptide; Cateslytin; Catestatin; Chromogranin A; Plasmepsins II and IV; Plasmodium falciparum

Indexed keywords

ASPARTIC PROTEINASE; CATESTATIN; CHLOROQUINE; LACTATE DEHYDROGENASE; PLASMEPSIN II; PLASMEPSIN IV; UNCLASSIFIED DRUG; CHROMOGRANIN A; CHROMOGRANIN A (344 364); CHROMOGRANIN A (344-364); PEPTIDE FRAGMENT; PLASMEPSIN;

ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; GROWTH INHIBITION; MICROBIAL GROWTH; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; ANIMAL; CATTLE; CHEMISTRY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; SYNTHESIS;

BOVINAE; PLASMODIUM FALCIPARUM;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CATTLE; CHROMOGRANIN A; DOSE-RESPONSE RELATIONSHIP, DRUG; L-LACTATE DEHYDROGENASE; PEPTIDE FRAGMENTS; PLASMODIUM FALCIPARUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949507265     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-009-0235-8     Document Type: Article

References (66)

1. Metz-Boutigue MH, Kieffer AE, Goumon Y, Aunis D (2003) Innate immunity: involvement of new neuropeptides. Trends Microbiol 11:585-592 (Pubitemid 37500910)
2. Briolat J, Wu SD, Mahata SK, Gonthier B, Bagnard D, ChasserotGolaz S, Helle KB, Aunis D, Metz-Boutigue MH (2005) New antimicrobial activity for the catecholamine release-inhibitory peptide from chromogranin A. Cell Mol Life Sci 62:377-385
3. Strub JM, Garcia-Sablone P, Lonning K, Taupenot L, Hubert P, Van Dorsselaer A, Aunis D, Metz-Boutigue MH (1995) Processing of chromogranin B in bovine adrenal medulla. Identification of secretolytin, the endogenous C-terminal fragment of residues 614-626 with antibacterial activity. Eur J Biochem 229:356-368
4. GoumonY,StrubJM,MoniatteM,NullansG,PoteurL,HubertP,VanDorsselaerA,AunisD, Metz-BoutigueMH(1996)TheC-terminalbisphosphorylatedproenkephalin-A-(209-237) -peptidefromadrenalmedullarychromaffingranulespossessesantibacterialactivity. EurJBiochem235:516-525(Pubitemid26061879)
5. Kieffer AE, Goumon Y, Ruh O, Chasserot-Golaz S, Nullans G, Gasnier C, Aunis D, Metz-Boutigue MH (2003) The N- and C-terminal fragments of ubiquitin are important for the antimicrobial activities. FASEB J 17:776-778
6. Lugardon K, Chasserot-Golaz S, Kieffer AE, Maget-Dana R, Nullans G, Kieffer B, Aunis D, Metz-Boutigue MH (2001) Structural and biological characterization of chromofungin, the antifungal chromogranin A-(47-66)-derived peptide. J Biol Chem 276:35875-35882 (Pubitemid 37384394)
7. Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH (2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 275:10745-10753 (Pubitemid 30212702)
8. Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D (1993) Intracellular and extracellular processing of chromogranin A: determination of cleavage sites. Eur J Biochem 217:247-257 (Pubitemid 23305293)
9. Helle KB, Corti A, Metz-Boutigue MH, Tota B (2007) The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 64:2863-2886 (Pubitemid 351152248)
10. MahataSK,O'ConnorDT,MahataM,YooSH,TaupenotL,Wu,GillBM,ParmerRJ(1997) Novelautocrinefeedbackcontrolofcatecholaminerelease: adiscretechromograninAfragmentisanoncompetitivenicotiniccholinergicantagonist. JClinInvest100:1623-1633(Pubitemid27425790)
11. Mahata SK, Mahata M, Yoo SH, Taupenot L, Wu H, Aroda VR, Livsey CV, Taulane JP, Goodman M, Parmer RJ, O'Connor DT (1998) A novel, catecholamine release-inhibitory peptide from chromogranin A: autocrine control of nicotinic cholinergicstimulated exocytosis. Adv Pharmacol 42:260-264
12. Lee JC, Taylor CV, Gaucher SP, Toneff T, Taupenot L, Yasothornsrikul S, Mahata SK, Sci C, Parmer RJ, Neveu JM, Lane WS, Gibson BW, O'Connor DT, Hook VY (2003) Primary sequence characterization of Cts intermediates and peptides defines proteolytic cleavage sites utilized for converting chromogranin A into active Cts secreted from neuroendocrine chromaffin cells. Biochemistry 42:6938-6946
13. Helman LJ, Ahn TG, Levine MA, Allison A, Cohen PS, Cooper MJ, Cohn DV, Israel MA (1988) Molecular cloning and primary structure of human chromogranin A (secretory protein I) cDNA. J Biol Chem 263:11559-11563
14. IacangeloA,AffolterHU,EidenLE,HerbertE,GrimesM(1986) BovinechromograninAsequenceanddistributionofitsmessengerRNAinendocrinetissues. Nature10:82-86(Pubitemid16012355)
15. WuHJ,RozanskyDJ,ParmerRJ,GillBM,O'ConnorDT(1991) StructureandfunctionofthechromograninAgeneClues-evolutionandtissue- specificexpression.JBiolChem15:13130-13134(Pubitemid21907319)
16. Iacangelo A, Okayama H, Eiden LE (1988) Primary structure of rat chromogranin A and distribution of its mRNA. FEBS Lett 227:115-121 (Pubitemid 18033861)
17. Sato F, Hasegawa T, Katayama Y, Iwanaga T, Yanaihara N (2000) Molecular cloning of equine chromogranin A and its expression in endocrine and exocrine tissues. J Vet Med Sci 62:953-959
18. Iacangelo AL, Eischer-Colbrie R, Koller KJ, Brownstein MJ, Eiden LE (1988) The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin. Endocrinology 122:2339-2341
19. TurquierV,VaudryH,JégouS,AnouarY(1999) FrogchromograninAmessengerribonucleicacidencodesthreehighlyconservedpeptidesC oordinateregulationofproopiomelanocortinandchromograninAgeneexpressioninthep arsintermediaofthepituitaryduringbackgroundcoloradaptation.Endocrinology140: 4104-4112(Pubitemid30647107)
20. Radek KA, Lopez-Garcia B, Hupe M, Niesman IR, Elias PM, Taupenot L, Mahata SK, O'Connor DT, Gallo RL (2008) The neuroendocrine peptide catestatin is a cutaneous antimicrobial and induced in the skin after injury. J Invest Dermatol 128:1525-1534 (Pubitemid 351693209)
21. Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF, Vidic J, de Barry J, Chasserot-Golaz S, Delalande F, Van Dorsselaer A, Schneider F, Helle K, Aunis D, Prévost G, MetzBoutigue MH (2009) Two chromogranin a-derived peptides induce calcium entry in human neutrophils by calmodulinregulated calcium independent phospholipase A2. PLoS One 4(2):e4501
22. Breman JG (2001) The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden. Am J Trop Med Hyg 64:1-11
23. World Health Organization (2005) http://www.rollbackmalar.ia. org/wmi-2005/
24. Snow RW, Korenromp EL, Gouws E (2004) Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg 71:16-24
25. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 434:214-217
26. Laufer MK, Plowe CV (2004) Withdrawing antimalarial drugs: impact on parasite resistance and implications for malaria treatment policies. Drug Resist Update 7:279-288
27. Baird JK (2005) Effectiveness of antimalarial drugs. N Engl J Med 352:1565-1577
28. FidockDA,RosenthalPJ,CroftSL,BrunR,NwakaS(2004)Antimalarialdrugdiscovery: efficacymodelsforcompoundscreening.NatRevDrugDiscov3:509-520(Pubitemid38807533)
29. Biagini GA, O'Neill PM, Nzila A, Ward SA, Bray PG (2003) Antimalarial chemotherapy: young guns or back to the future? Trends Parasitol 19:479-487
30. Go ML (2003) Novel antiplasmodial agents. Med Res Rev 23:456-487
31. Goldberg DE, Slater AF, Cerami A, Henderson GB (1990) Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc Natl Acad Sci USA 87:2931-2935
32. Bjelic S, Nervall M, Gutiérrez-de-Terán H, Ersmark K, Hallberg A, Aqvist J (2007) Computational inhibitor design against malaria plasmepsins. Cell Mol Life Sci 64(17):2285-2305 (Pubitemid 47347955)
33. Johansson PO, Chen Y, Belfrage AK, Blackman MJ, Kvarnstrom I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B (2004) Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II Use of solidphase synthesis to explore novel statine motifs. J Med Chem 47:3353-3366
34. Liu P, Marzahn MR, Robbins AH, Gutiérrez-de-Terán H, Rodríguez D, McClung SH, Stevens SM Jr, Yowell CA, Dame JB, McKenna R, Dunn BM (2009) Recombinant plasmepsin 1 from the human malaria parasite Plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis. Biochemistry 48(19):4086-4099
35. Boss C, Richard-Bilstein S, Weiler T, Eischli W, Meyer S, Binkert C (2003) Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents. Curr Med Chem 10:883-907
36. Jean-Francois F, Khemtemourian L, Odaert B, Castano S, Grelard A, Manigand C, Bathany K, Metz-Boutigue MH, Dufourc EJ (2007) Variability in secondary structure of the antimicrobial peptide Cateslytin in powder, solution, DPC micelles and at the air-water interface. Eur Biophys J 36:1019-1027 (Pubitemid 350045035)
37. Trager W, Jensen JB (1997) Continuous culture of Plasmodium falciparum: its impact on malaria research. Int J Parasitol 27:989-1006
38. Schuster FL (2002) Cultivation of Plasmodium spp. Clin Microbiol Rev 15:355-364
39. Trager W, Jensen JB (2005) Human malaria parasites in continuous culture. 1976. J Parasitol 91:484-486 (Pubitemid 40993432)
40. Lelievre J, Berry A, Benoit-Vical F (2005) An alternative method for Plasmodium culture synchronization. Exp Parasitol 109:195-197
41. Kaddouri H, Nakache S, Houze S, Mentre F, Le Bras J (2006) Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother 50:3343-3349 (Pubitemid 44527508)
42. Benting J, Mattei D, Lingelbach K (1994) Brefeldin A inhibits transport of the glycophorin-binding protein from Plasmodium falciparum into the host erythrocyte. Biochem J 300:821-826
43. Doderer C, Heschung A, Guntz P, Cazenave JP, Hansmann Y, Senegas A, Pfaff AW, Abdelrahman T, Candolfi E (2007) A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies. Malar J 6:19
44. Peng J, Schwartz D, Elias JE, T horeen CC, Cheng D, Marsischky G, Roelofs J, Finley D, Gygi SP (2003) A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 21:921-926 (Pubitemid 36936199)
45. Elias JE, Gibbons ED, King OD, Roth FP, Gygi SP (2004) Intensity-based protein identification by machine learning from a library of tandem mass spectra. Nat Biotechnol 22:214-219
46. Westling J, Yowell CA, Majer P, Erickson JW, Dame JB, Dunn BM (1997) Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. Exp Parasitol 87:185-193
47. Bonilla JA, Moura PA, Bonilla TD, Yowell CA, Fidock DA, Dame JB (2007) Effects on growth, hemoglobin metabolism and paralogous gene expression resulting from disruption of genes encoding the digestive vacuole plasmepsins of Plasmodium falciparum, Int J Parasitol 37:317-327
48. Jiang S, P rigge ST, Wei L, Gao Y, Hudson TH, Gerena L, Dame JB, Kyle DE (2001) New class of small nonpeptidyl compounds blocks Plasmodium falciparum development in vitro by inhibiting plasmepsins. Antimicrob Agents Chemother 45:2577-2584
49. Zhang D, Shooshtarizadeh P, Laventie BJ, Colin DA, Chich JF Vidic J, de Barry J, Chasserot-Golaz S, Delalande F, Van Dorsselaer A, Schneider F, Helle K, Aunis D, Prévost G, Metz-Boutigue MH (2009) Two chromogranin A-derived peptides induce calcium entry in human neutrophils by calmodulin-regulated calcium independent phospholipase A2. PLoS ONE 4(2): e4501. Published online 2009 Feb 19. doi: 10.1371/ joumal.pone.0004501
50. GwadzRW,KaslowD,LeeJY,MaloyWL,ZasloffM,MillerLH(1989) Effectsofmagaininsandcecropinsonthesporogonicdevelopmentofmalariaparasitesinmo squitoes.InfectImmun57(9):2628-2633(Pubitemid19212590)
51. Shahabuddin M, Fields I, Bulet P, Hoffmann JA, Miller LH (1998) Plasmodium gallinaceum: differential killing of some mosquito stages of the parasite by insect defensin. Exp Parasitol 89(1):103-112 (Pubitemid 28377379)
52. Ghosh JK, Shaool D, Guillaud P, Cicerón L, Mazier D, Kustanovich I, Shai Y, Mor A (1997) Selective cytotoxicity of dermaseptin S3 toward intraerythrocytic Plasmodium falciparum and the underlying molecular basis. J Biol Chem 272(50):31609-31616
53. Conde R, Zamudio FZ, Rodriguez MH, Possani LD (2000) Scorpine, an anti-malaria and anti-bacterial agent purified from scorpion venom. FEBS Lett 471(2-3):165-168 (Pubitemid 30190058)
54. Jaynes JM, Burton CA, Barr SB, Jeffers GW, Julian GR, White KL, Enright FM, Klei TR, Laine RA (1988) In vitro cytocidal effect of novel lytic peptides on Plasmodium falciparum and Trypanosoma cruzi. FASEB J 2(13):2878-2883
55. Rodriguez MC, Zamudio F, Torres JA, Gonzalez-Ceron L, Possani LD, Rodriguez MH (1995) Effect of a cecropin-like synthetic peptide (Shiva-3) on the sporogonic development of Plasmodium berghei. Exp Parasitol 80(4):596-604
56. Possani LD, Zurita M, Delepierre M, Hernández FH, Rodríguez MH (1998) From noxiustoxin to Shiva-3, a peptide toxic to the sporogonic development of Plasmodium berghei. Toxicon 36(11):1683-1692 (Pubitemid 28511083)
57. Ghosh AK, Ribolla PE, Jacobs-Lorena M (2001) Targeting Plasmodium ligands on mosquito salivary glands and midgut with a phage display peptide library. Proc Natl Acad Sci USA 98(23): 13278-13281
58. Arrighi RB, Nakamura C, Miyake J, Hurd H, Burgess JG (2002) Design and activity of antimicrobial peptides against sporogonicstage parasites causing murine malarias. Antimicrob Agents Chemother 46(7):2104-2110 (Pubitemid 34665903)
59. Mason AJ, Moussaoui W, Abdelrahman T, Boukhari A, Bertani P, Marquette A, Shooshtarizaheh P, Moulay G, Boehm N, Guerold B, Sawers RJ, Kichler A, Metz-Boutigue MH, Candolfi E, Prévost G, Bechinger B (2009) Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides. J Biol Chem 284(1):119-133
60. Fennell BJ, Naughton JA, Dempsey E, Bell A (2006) Cellular and molecular actions of dinitroaniline and phosphorothioamidate herbicides on Plasmodium falciparum: tubulin as a specific antimalarial target. Mol Biochem Parasitol 145:226-238
61. Kappes B, Rohrbach P (2007) Microtubule inhibitors as a potential treatment for malaria. Future Microbiol 2:409-423 (Pubitemid 47365026)
62. Gupta A, Mehra P, Dhar SK (2008) Plasmodium falciparum origin recognition complex subunit 5: functional characterization and role in DNA replication foci formation. Mol Microbiol 69:646-665
63. Ersmark K, Nervall M, Gutierrez-de-Teran H, Hamelink E, demente Janka LK, JC Dunn BM, Gogoli A, Samuelsson B, Qvist J, Hallberg A (2006) Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV. Bioorg Med Chem 14:2197-2208 (Pubitemid 43256689)
64. Ersmark K, Samuelsson B, Hallberg A (2006) Plasmepsins as potential targets for new antimalarial therapy. Med Res Rev 26:626-666 (Pubitemid 44230415)
65. Bonilla JA, Bonilla TD, Yowell CA, Fujioka H, Dame JB (2007) Critical roles for the digestive vacuole plasmepsins of Plasmodium falciparum in vacuolar function. Mol Microbiol 65:64-75
66. Ersmark K, Nervall M, Hamelink E, Janka LK, demente JC, Dunn BM, Blackman MJ, Samuelsson B, Aqvist J, Hallberg A (2005) Synthesis of malarial plasmepsin inhibitors and prediction of binding modes by molecular dynamics simulations. J Med Chem 48:6090-6106